Brokerages Set GoodRx Holdings, Inc. (NASDAQ:GDRX) Price Target at $9.36

Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) have received an average recommendation of “Moderate Buy” from the fifteen research firms that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $9.36.

Several research analysts have issued reports on the company. Raymond James upgraded GoodRx from an “outperform” rating to a “strong-buy” rating and set a $10.00 price objective for the company in a research report on Friday, August 9th. UBS Group cut their price target on shares of GoodRx from $9.00 to $8.50 and set a “neutral” rating for the company in a report on Friday, August 9th. Morgan Stanley boosted their price objective on shares of GoodRx from $7.00 to $9.50 and gave the stock an “equal weight” rating in a report on Monday, June 10th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $10.00 target price on shares of GoodRx in a report on Friday, August 16th. Finally, Citigroup reduced their price target on shares of GoodRx from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Friday, August 9th.

Insiders Place Their Bets

In related news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $7.86, for a total transaction of $83,921.22. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 4.17% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On GoodRx

Institutional investors have recently modified their holdings of the company. Victory Capital Management Inc. raised its holdings in GoodRx by 47.5% in the 4th quarter. Victory Capital Management Inc. now owns 31,760 shares of the company’s stock valued at $213,000 after acquiring an additional 10,225 shares during the last quarter. Jump Financial LLC grew its position in shares of GoodRx by 568.7% in the fourth quarter. Jump Financial LLC now owns 147,011 shares of the company’s stock valued at $985,000 after purchasing an additional 125,028 shares during the period. Trexquant Investment LP lifted its position in GoodRx by 396.6% during the fourth quarter. Trexquant Investment LP now owns 155,853 shares of the company’s stock worth $1,044,000 after buying an additional 124,468 shares during the period. US Bancorp DE lifted its position in GoodRx by 11.1% during the fourth quarter. US Bancorp DE now owns 105,941 shares of the company’s stock worth $710,000 after buying an additional 10,588 shares during the period. Finally, Innealta Capital LLC acquired a new stake in GoodRx in the 4th quarter worth about $91,000. Institutional investors and hedge funds own 63.77% of the company’s stock.

GoodRx Stock Down 1.2 %

GDRX stock opened at $7.59 on Friday. GoodRx has a one year low of $4.14 and a one year high of $9.26. The company has a debt-to-equity ratio of 0.96, a quick ratio of 7.32 and a current ratio of 7.32. The company has a fifty day moving average of $8.02 and a 200-day moving average of $7.61. The stock has a market capitalization of $2.85 billion, a PE ratio of -759.00, a price-to-earnings-growth ratio of 3.55 and a beta of 1.38.

GoodRx (NASDAQ:GDRX) last announced its quarterly earnings data on Thursday, August 8th. The company reported $0.08 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). The business had revenue of $200.60 million during the quarter, compared to analysts’ expectations of $200.47 million. GoodRx had a negative net margin of 7.57% and a positive return on equity of 3.63%. GoodRx’s revenue for the quarter was up 5.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.02 EPS. As a group, analysts expect that GoodRx will post 0.15 EPS for the current year.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.